03204nam 22006494a 450 991077869740332120200520144314.01-282-39794-X978661239794390-474-3259-210.1163/ej.9789004164451.I-482(CKB)1000000000821781(EBL)468030(OCoLC)593222478(SSID)ssj0000336423(PQKBManifestationID)11248698(PQKBTitleCode)TC0000336423(PQKBWorkID)10281930(PQKB)10580496(MiAaPQ)EBC468030(OCoLC)186976052(OCoLC)217989380(nllekb)BRILL9789047432593(Au-PeEL)EBL468030(CaPaEBR)ebr10363791(CaONFJC)MIL239794(PPN)184923522(EXLCZ)99100000000082178120080306d2008 uy 0engur|n|---|||||txtccrA cumulative bibliography of medieval military history and technology[electronic resource] update 2003-2006 /by Kelly DeVriesLeiden ;Boston Brill20081 online resource (504 p.)History of warfare,1385-7827 ;v. 46Includes index.90-04-16445-6 Preliminary Materials /K. Devries -- Medieval military history and technology update 2006 /K. Devries -- Premodern military history bibliography new publications, 2003–2006 /K. Devries -- Index /K. Devries.This is the second update of A Cumulative Bibliography of Medieval Military History and Technology , which appeared in 2002. It is meant to do two things: to present references to works on medieval military history and technology not included in the first two volumes; and to present references to all books and articles published on medieval military history and technology from 2003 to 2006. These references are divided into the same categories as in the first two volumes and cover a chronological period of the same length, from late antiquity to 1648, again in order to present a more complete picture of influences on and from the Middle Ages. It also continues to cover the same geographical area as the first and second volume, in essence Europe and the Middle East, or, again, influences on and from this area. The languages of these bibliographical references reflect this geography.History of warfare ;v. 46.Military art and scienceHistoryMedieval, 500-1500BibliographyMilitary history, MedievalBibliographyMilitary art and scienceAutomationBibliographyMilitary art and scienceHistoryMilitary history, MedievalMilitary art and scienceAutomation016.35500940902DeVries Kelly1956-779268MiAaPQMiAaPQMiAaPQBOOK9910778697403321Cumulative Bibliography of Medieval Military History and Technology1670833UNINA03928nam 2200949z- 450 991036775390332120231214133528.03-03921-587-6(CKB)4100000010106178(oapen)https://directory.doabooks.org/handle/20.500.12854/40955(EXLCZ)99410000001010617820202102d2019 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierAnticancer DrugsMDPI - Multidisciplinary Digital Publishing Institute20191 electronic resource (214 p.)3-03921-586-8 The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.graphene oxideindoleandrogenscyclooxygenase-2cyclooxygenase-1heteropolysaccharidedrug conjugationdrug deliveryellipticinechemical linkeroesophageal cancerantiproliferative activitytopoisomerase II?-lactamDSDantibodytopoisomerase inhibitorsmagnetic targetingcisplatin resistancesteroidogenesis[18F]FDG PET/CTheterocyclic chemistrydehydroepiandrosteroneantimitotic3-vinylazetidin-2-onesglioblastomaand cancer therapyintestinal mucositisCombretastatin A-4metabolismanti-cancer drugsmaghemiteCOX-1 inhibitoranticancerCYP17A1conjugate and hybrid drugsinflammationsnticancer drugsP450c17tumorigenesiscisplatinbiomarker profilingcancer drug designtubulincytochrome P4505-fluorouracilprostate cancerabirateroneNCI screenradiationcancer immunotherapymicrotubule targeted drugscancertreatment resistanceO’Boyle Niamh Mauth1296346Meegan Mary JauthBOOK9910367753903321Anticancer Drugs3024025UNINA